Compare CRESY & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | DNA |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.3M | 835.7M |
| IPO Year | 1997 | 2020 |
| Metric | CRESY | DNA |
|---|---|---|
| Price | $10.74 | $9.95 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 2 | 3 |
| Target Price | ★ $15.86 | $8.00 |
| AVG Volume (30 Days) | 206.5K | ★ 3.3M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $19.02 | $13.05 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.26 | $5.37 |
| 52 Week High | $14.21 | $18.22 |
| Indicator | CRESY | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 47.32 |
| Support Level | $10.52 | $6.54 |
| Resistance Level | $11.74 | $11.12 |
| Average True Range (ATR) | 0.42 | 0.98 |
| MACD | -0.07 | -0.38 |
| Stochastic Oscillator | 19.21 | 13.32 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.